What is the difference between Emgality and Ajovy?

Same class. Both Emgality and Ajovy are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.

Are Emgality and Ajovy the same drug?

No. Emgality is the brand name for Galcanezumab and Ajovy is the brand name for Fremanezumab. They are different active ingredients.

Is Emgality a tablet or an injection?

Emgality is given by the subcutaneous route; Ajovy by the subcutaneous route.

Who makes Emgality and Ajovy?

Emgality is marketed by Eli Lilly; Ajovy by Teva. (FDA application holder, per Drugs@FDA.)

Emgality vs Ajovy: How Galcanezumab and Fremanezumab Compare

At a glance

EmgalityGalcanezumab

AjovyFremanezumab

Brand name

Emgality

Ajovy

Drug class

CGRP inhibitor

Route

Subcutaneous

Marketed by

Eli Lilly

Teva

First FDA approval

27 Sep 2018

14 Sep 2018

US shortage

Not listed

Key differences

Same class. Both Emgality and Ajovy are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.
How they are taken. Both are given by the subcutaneous route.
Time on the market. Emgality was first approved by the FDA in 2018, Ajovy in 2018.
Who markets them. Emgality is marketed by Eli Lilly; Ajovy by Teva.

What each one treats

EmgalityGalcanezumab

EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) 1.1 Migraine EMGALITY is indicated for the preventive treatment of migraine in adults. 1.2 Episodic Cluster Headache EMGALITY is indicated for the treatment of episodic cluster headache in adults.

AjovyFremanezumab

AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. AJOVY is a calcitonin gene-related peptide antagonist indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. ( 1 )

How each one works

EmgalityCGRP inhibitor

12.1 Mechanism of Action Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

AjovyCGRP inhibitor

12.1 Mechanism of Action Fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Related comparisons

Aimovig VS Emgality Aimovig VS Ajovy Emgality VS Nurtec ODT Emgality VS Ubrelvy Ajovy VS Nurtec ODT Ajovy VS Ubrelvy

Emgality profile Ajovy profile CGRP Inhibitors All comparisons

This is not medical advice, and not a recommendation of one drug over the other.

Which medicine is right for a given person depends on their diagnosis, other conditions, other medicines, kidney and liver function, pregnancy, and cost or reimbursement — none of which this page knows. Two drugs in the same class are not automatically interchangeable. Never start, stop or switch a prescription medicine on the basis of a web page; that decision belongs to you and your clinician or pharmacist.

Class and summary text is written by the Priya Life Science editorial team. Label, mechanism, route, manufacturer and approval data come from the U.S. FDA via the openFDA API; shortage status from the FDA Drug Shortage Database. Approvals, indications and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions — a drug approved in one may not be approved, or may carry a different name, in another.

Emgality vs Ajovy

At a glance

Key differences

What each one treats

How each one works

Related comparisons

Read more